Interviews

Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.

Having one of the lowest adult HIV prevalence rates in the world is a significant public health success story, explained Jason Myers, PhD, CEO of the New Zealand AIDS Foundation.

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how doctors are managing patients who present with later-stage cancers as a result of barriers to screening measures imposed by the pandemic.

David McIntyre, MD, FRACP, describes lessons learned from the pandemic for ensuring appropriate continuation of care for pregnant patients with diabetes.

Aleksandar Kostic, PhD, an assistant professor of microbiology at Harvard Medical School, outlines what needs to happen next in his research developing a type 1 diabetes (T1D) vaccine.

Outcome inconsistency in randomized controlled trials for pneumonia could create issues for interpreting data and compiling research going forward, said Alexander Mathioudakis, MD, MRCP, at the European Respiratory Society annual meeting.

Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.

Adolescents and adults are affected differently by vaping and have different health concerns, according to Ilona Jaspers, PhD, director of toxicology and the deputy director of the Center for Environmental Medicine, Asthma, and Lung Biology at the Gillings School of Global Public Health at the University of North Carolina.

Tonya Winders, MBA, CEO and president of the Allergy & Asthma Network, lists the major current issues with current asthma care guidelines at the European Respiratory Society (ERS) International Congress 2021.

Michael E. Wechsler, MD, a pulmonologist at National Jewish Health, explains the role that eosinophils play in everyday health and disease development.

At ERS 2021, Ilona Jaspers, PhD, discusses some of the major health concerns associated with teenagers and young adults vaping.

Using the argument that regularly taking medication is a great way to earn parents' trust is a great tactic to encourage children and teenagers to remain adherent to their asthma therapies, said William "Andy" Nish, MD, an allergist and immunologist in Georgia.

Being a full-service dermatology practice helps make patients' lives easier when they have skin cancer, explained Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

Many young people develop resistance to antiretroviral treatment or they experience lipoatrophy; many also have metabolic complications or inflammation via immune activation, noted Allison Agwu, MD, ScM, FAAP, FIDSA, Johns Hopkins University School of Medicine.

Hilary Pinnock, MD, talks about what her session at the European Respiratory Society International Congress 2021 will cover and other sessions that she's excited to check out.

Tonya Winders, MBA, CEO and president of the Allergy & Asthma Network, highlights what she is looking forward to at the European Respiratory Society (ERS) International Congress 2021.

On this episode of Managed Care Cast, we speak with Ellen Kelsay, president and CEO of the Business Group on Health, on the findings from her organization's 2022 Large Employers’ Health Care Strategy and Plan Design Survey.

Ezio Bonifacio, PhD, describes the benefits of screening children for type 1 diabetes and what preventive interventions may be possible.

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the role that sodium glucose co-transporter (SGLT) inhibitors play in patients with diabetes and diminished glomerular filtration rates.

Switching patients with asthma to a biologic medication purely because that patient is not adherent to inhaled medications gets in the way of a physician's goal of being good stewards of patient care and finances, said William "Andy" Nish, MD.

In patients with heart failure and diabetes, sotagliflozin can lower glucose quite well, even when patients are facing suboptimal glomerular filtration rates, noted Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital and Harvard Medical School.

Both REDUCE-IT and STRENGTH recruited people with very high triglycerides and tested different formulations of omega-3 fatty acids, but the results were different. About 12% of the difference can be explained, noted Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, but 13% cannot be, given that REDUCE-IT had a 25% reduced risk of atherosclerotic cardiovascular disease.

There was a reduction in both the need for dialysis and progression to end-stage renal disease; finerenone was really well tolerated, stated Bertram Pitt, MD, professor of medicine emeritus, University of Michigan School of Medicine.

With finerenone being a targeted therapy, data show there may be an additive cardiorenal benefit when it is coadministered with a sodium glucose co-transporter 2 inhibitor, noted Dipti Itchhaporia, MD, FACC, FAHA, FESC, president of the American College of Cardiology.

Whatever your theory of heart failure with preserved ejection fraction, sodium glucose co-transporter 2 (SGLT2) inhibitors seem to be attacking every one, noted Javed Butler, MD, MPH, MBA, University of Mississippi.

Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the anticipation for more biosimilars to enter the oncology market and the current level of interest in the pipeline.